12 Dec, 12:49 - Indian

SENSEX 81356.3 (-0.21)

Nifty 50 24579.25 (-0.25)

Nifty Bank 53232.65 (-0.30)

Nifty IT 45822.3 (1.04)

Nifty Midcap 100 59068.15 (-0.38)

Nifty Next 50 73239.7 (-0.07)

Nifty Pharma 22212.45 (-0.40)

Nifty Smallcap 100 19489.95 (-0.85)

12 Dec, 12:49 - Global

NIKKEI 225 39849.14 (1.21)

HANG SENG 20433.95 (1.38)

S&P 6096.5 (-0.14)

LOGIN HERE

Torrent Pharmaceuticals Ltd

You are Here : Home > Markets > CompanyInformation > Company Background
BSE Code : 500420 | NSE Symbol : TORNTPHARM | ISIN : INE685A01028 | Industry : Pharmaceuticals |


Chairman's Speech

Celebrating Legacy, Shaping Tomorrow

The global pharmaceutical industry witnessed a notable surge in spending in 2023, indicating a positive trajectory for medicine expenditure through 2028, fueled by strong growth in emerging markets.

Samir Mehta

Executive Chairman

Dear Stakeholders,

It gives me immense pleasure to present that Torrent Pharma made significant progress on multiple fronts during the fiscal year 2023-24. This year holds special significance as we commemorate the 100th birth anniversary of our visionary founder, Shri Uttambhai Nathalal Mehta. His journey from a medical representative to building a leading global pharmaceutical company continues to inspire us. His commitment to making affordable medicines and pioneering indigenous production remains the cornerstone of our values and mission.

As we move ahead, we are taking the legacy of the last five decades of journey to further strengthen the Company's position in the market and drive sustainable growth while creating value for stakeholders.

Economic Context and Industry Overview

The global economy has demonstrated resilience despite significant challenges, including supply-chain disruptions following the pandemic and a crisis triggered by the Russian-Ukraine conflict, leading to spikes in energy and food prices and substantial inflation. However, contrary to expectations, these events did not push the world into recession. The banking system remained robust, and major emerging markets avoided severe economic halts. Global growth hit a low of 2.3% in late 2022, coinciding with a peak in inflation at 9.4%. Looking ahead, growth is expected to stabilise around 3.2% for 2024 and 2025. Overall, indicators suggest a favourable economic trajectory with signs of a controlled adjustment.

The Indian economy displayed robust growth in FY24, with an estimated GDP growth of 7.8%, driven by strong private consumption and government capital expenditure. Sectors like construction and manufacturing played pivotal role, with double-digit growth rates. Despite inflation concerns, which moderated to 5.1% by February 2024, the Reserve Bank of India maintained a cautious stance for price stability. Looking ahead, India's economic outlook remains promising, with a projected growth rate of 6.8% for FY25, driven by private consumption and infrastructure investment.

The global pharmaceutical industry witnessed a notable surge in spending in 2023, indicating a positive trajectory for medicine expenditure through 2028, fuelled by strong growth in emerging markets.

Overall, the industry is poised for sustained growth and innovation, driven by emerging markets and therapeutic advancements, despite facing challenges. The Indian pharmaceutical industry, known for its quality and affordability, is poised for strong growth. Factors such as a growing population, demographic shifts, and government incentives like the PLI scheme are driving this growth. India's expertise in low-cost manufacturing ensures competitive pricing, while rising incomes and improved healthcare infrastructure enhance affordability and access to modern medicines nationwide.

Delivering Robust Performance

In 2023–24, we continued our growth momentum with a year-on-year healthy revenue growth of 12% and Operating EBITDA growth of 19%. Our operating profitability witnessed a notable improvement of approximately 5% over the past 5 years driven by enhanced operational efficiencies, strategic investments and strong market performance in branded markets.

I am pleased to share that our Bileshwarpura facility received regulatory clearance from the USFDA and commenced commercial operations. We successfully launched our first oncology product from this facility, marking a significant milestone in our expansion efforts and commitment to delivering innovative therapies. During the year, the USFDA also cleared our Dahej Facility which paves way for the new product approvals in the US market.

Our Indian business continued to deliver strong performance, contributing approximately 53% of our revenues, supported by strong performance of top brands, new launch momentum, market share gains in our focus therapies and strong growth in Curatio acquired portfolio. The company also entered into strategic alliance with Zydus Lifesciences Ltd which will strengthen our gastroenterology portfolio while addressing the growing patients' needs in NASH and NAFLD. Going forward, we expect India business to continue outperforming the market growth. We remain committed to expanding market share in all our focus therapies, improve field force productivity in the expanded areas, prioritising new product launches, and continue building the consumer health business.

In Brazil, Torrent Pharma has established itself as a leading player, navigating through patent law changes and market fluctuations with resilience. However, our commitment to growth is further exemplified by our strategic initiatives. Firstly, we have accelerated new product launches in both branded (BGx) and generic (Gx) segments. Secondly, we are focused on expanding our portfolio in CNS, Diabetes, Cardiovascular and adding two new therapeutic segment in the coming years. In ROW markets, we continue to remain focused on brand building, expansion of existing and new therapeutic areas. In Germany, amidst shifting market dynamics and rising competition, our efforts are directed towards improving cost competitiveness and refining tender bidding strategies in the generics market, particularly for high volume and niche products, which have yielded positive results. We are also placing increased emphasis on over-the-counter (OTC) and specialty channels such as hospitals, which show promising growth prospects. Moving forward, we intend to maintain our market position by persisting with cost optimisation initiatives, expanding our product range, and solidifying our presence in critical market segments In the US, new product approvals are expected to give a positive momentum to the overall performance. At the year-end, 34 ANDAs were pending approval with the USFDA.

We continue to prioritise key countries such as Mexico and the Philippines as growth engines among second-tier markets, alongside other markets to strengthen our global footprint and capitalise on new opportunities for expansion.

Going Beyond Business

At Torrent Pharma, we are dedicated to sustainability and responsible practices. We have set ambitious targets to reduce our greenhouse gas emissions and are actively exploring innovative methods to minimise our environmental impact. By diversifying our energy mix with cleaner fuels and renewable sources and investing in projects like the Hybrid Solar-Wind initiative, we aim to significantly reduce our carbon footprint.

In addition to managing energy and emissions, we prioritise water conservation through initiatives such as rainwater harvesting and responsible freshwater consumption. Our goal is to achieve 100% non-hazardous recycling and zero waste at landfill sites, reflecting our commitment to environmental stewardship.

As part of our corporate social responsibility philosophy, we strive to positively impact communities in three key areas: Community Healthcare, Sanitation and Hygiene, Education and Knowledge Enhancement and Social Care and Concern. Through our initiatives in the areas of healthcare like preventive healthcare programmes, enhancing women health & hygiene and providing access to as specialist medical services through proactive interventions, including awareness campaigns and educational support, we aim to improve lives and promote well-being of the Community.

Outlook

Looking ahead, we aim to consolidate and strengthen our market position in the branded generic markets, focus on improving field force productivity in the expanded areas, and further grow our consumer health business portfolio by strengthening our distribution channels and launching national media campaigns to bolster brand awareness and market presence. For generic markets, our focus will be to continue achieving cost competitiveness and strengthen the R&D pipeline through incremental filing and launches. Incremental cash generation shall be allocated toward further de-leveraging of balance sheet. Furthermore, we made significant progress on our ESG targets and will continue reducing our carbon footprint and environmental impact through various initiatives.

We express our gratitude to our employees and stakeholders for their trust and support, and we are committed to fostering these relationships to create enduring value and drive sustainable growth. Regards,

SAMIR MEHTA

Executive Chairman